Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Thirty-four patients with advanced malignant melanoma received AZQ (an aziridinylbenzoquinone) at a dose of 22.5 or 27.5 mg/m2/month iv. Objective regressions among 23 previously untreated and 11 previously treated patients were two and none, respectively. Hematologic toxicity was dose-limiting.